|
Published by: SMI Publishing, Ltd
Published: Mar. 18, 2003
Table of Contents
- DAY 1
- 8.30 Registration and Coffee
- 9.00 Chairman's Opening Remarks
- Dr Thomas Dooley, Chief Executive Officer, IntegriDerm.
- 9.10 DEVELOPMENT OF BOTANICAL HEALTH PRODUCTS
- Pitfalls and opportunities
- Developments in the botanical supplements market
- Highlights of botanical supplements, some examples
- Requirements for successful botanical health products
- Quality and safety aspects
- Efficacy and claims
- Perspectives for botanical health products
- Dr H Friso Smit, Senior Scientist, Numico Research.
- 9.40 FUNCTIONAL SKIN CARE COSMETICS
- Performance through the right choice of ingredients
- Filling the jar - what’s in a formulation?
- Differences between non-active excipients and active ingredients
- Understanding active ingredients are different in cosmetics and pharma - the cosmeceutical debate
- Labelling and regulatory aspects - a global challenge
- Claim substantiation is necessary - demonstration of proven effects
- Factors affecting the formulation of functional cosmetics
- Current and future trends
- Dr Peter Lersch, Head, Research & Development, Personal Care Actives, Degussa.
- 10.20 PAL-KTTKS, A PEPTIDE TO REPLACE RETINOL?
- Matrix regeneration by topical application of a lipophilic synthetic collagen I fragment
- Pal-KTTKS (Palmitoyl-Lys-Thr-Thr-Lys-Ser) stimulates collagen I, III, IV, GAG and fibronectin synthesis in human fibroblasts
- Human skin biopsies from surgery
- Gene expression connected to the wound healing responses of the skin
- 5 clinical tests in vivo
- Biopsies taken from human volunteers
- Peptides stable in cosmetic formulas
- Dr Karl Lintner, Managing Director, Sederma.
- 11.00 Morning Coffee
- 11.20 BIOTECHNOLOGY FOR PERSONAL CARE
- Biomaterials
- Types of biomaterials
- Repeat sequence proteins
- Silk elastin protein
- Its properties
- Potential uses
- Dr Raj Lad, Senior Director, Consumer Markets, Genencor.
- 12.00 MANAGEMENT OF DANDRUFF WITH COSMETIC PRODUCTS
- Recent advances in genetics and therapeutics
- Dandruff is now recognised to be caused by Malessezia restricta and globosa
- Stratum corneum disruption is a key histological feature
- Micro crystalline ZPT in a cosmetic shampoo formulation is the most cost effective therapy
- Dr John Gray, Medical Consultant, Hair Care External Relations, Procter & Gamble.
- 12.40 Networking Lunch
- 2.00 EXPLORING THE OPPORTUNITIES IN A POTENTIALLY HUGE MARKET
- The successful development of a cosmeceutical
- Guidelines for advertising claims
- Outlicensing versus direct selling
- Kinetin: a case study - The science behind the molecule - The business model
- Frank Massino, Chairman & Chief Executive Officer, Senetek.
- 2.40 DISCOVERY OF MELANOCYTE TYROSINASE INHIBITORS FOR USE AS TOPICAL SKIN LIGHTENERS
- Meeting an unmet market need for high quality skin pigmentation cosmeceuticals
- In vitro bioassays for the discovery of mammalian tyrosinase inhibitors
- Patent-pending highly-potent inhibitors of malanocyte pigmentation
- Discovery of melanocytic cell biomarkers using DermArray DNA microarrays
- Dr Thomas Dooley, Chief Executive Officer, IntegriDerm.
- 3.20 CLINICAL TRIALS
- The role of clinical trials in cosmetic development
- Clinical trial design
- Clinical trial endpoints and claim substantiation
- Current research findings
- Problems associated with clinical trials
- Advantages and disadvantages of different testing models
- Future trends in clinical trials
- Dr Betsy Hughes-Formella, Managing Director, Bioskin.
- 4.00 Chairman’s Closing Remarks followed by Afternoon Tea
- Close of Day One
- DAY 2
- 8.30 Re-registration and Coffee
- 9.00 Chairman's Opening Remarks
- Dr Bart De Wever, Business Development Director, SkinEthic Laboratories.
- 9.10 IN VITRO RECONSTITUTED HUMAN EPIDERMIS (RHE)
- An alternative for the prediction of in vivo skin absorption, metabolism and toxicological effects of chemicals
- Topical formulations: advantages and problems
- In vitro evaluation of anti-inflammatory molecules
- RHE as model to discriminate irritants from sentisizers
- In vitro percutaneous absorption and metabolism of hormones
- Conclusion
- Dr Alain Coquette, Head, Department of Biology, SGS Biopharma.
- 9.40 USING IN VITRO TISSUE MODELS TO ASSESS THE BIOCOMPATIBILITY OF CONSUMER PRODUCTS
- Reconstituted human epidermis and epithelia as product development tools
- Definition of tissue models
- The in vitro test approach
- Protocols for skin ‘mildness’ testing in vitro
- Ocular hazard of cosmetics in vitro
- The in vitro investment: cost-benefit analysis
- Dr Bart De Wever, Business Development Director, SkinEthic Laboratories.
- 10.20 IN VITRO TEST METHODS FOR ASSESSING EYE IRRITATION POTENTIAL OF PHARMACEUTICALS
- Industrial prevalidation of a new in vitro reconstituted human cornea model for ocular irritation
- Background and rationale
- The collaborative project
- The process of prevalidation
- Protocol standardisation
- Obtained results
- Future steps
- Dr Freddy Van Goethen, Principal Scientist & Study Director Genetic & In Vitro Toxicology, Johnson & Johnson.
- 11.00 Morning Coffee
- 11.20 THE USE OF AN IN VITRO RECONSTRUCTED HUMAN EPIDERMIS FOR THE IDENTIFICATION OF IRRITATING AND PHOTOTOXIC COMPOUNDS
- In vitro strategy for irritation and phototoxicity testing
- In vitro strategy in toxicity risk assessment
- Observation of irritancy in clinical and animal studies
- Correlation of in vivo studies and in vitro human epidermis model
- Assessment of the phototoxic potential of compounds using 3T3-NRU and 3-D human in vitro assays
- Comparison of in vivo and in vitro data
- Conclusion
- Dr Nathalie Alepee, Laboratory Manager, Pfizer.
- 12.00 ESTABLISHING THE SAFETY OF COSMETICS
- Approaches to safety evaluation: when to test, how to test
- Assessing safety of ingredients
- Assessing safety of products
- Is animal testing ever justified?
- How useful are the non-animal alternatives?
- Assessing safety of marketed products
- Dr Stuart Freeman, Director, Toxicology, GlaxoSmithKline Consumer Healthcare.
- 12.40 Networking Lunch
- 2.00 COSMETIC OR DRUG? CLAIMS AND PRESENTATION TO ENSURE EARLY MARKETING OF YOUR PRODUCT IN EUROPE
- Cosmetics vs drugs
- Examples of products that can be sold as medical products or as cosmetics
- Safety and efficacy requirements of drugs vs cosmetics
- Cosmetic labelling: declaration of ingredients
- How to chose between drug sales vs cosmetic sales
- Early marketing of your cosmetic to gain funds for drug development
- Dr Peter Lassoff, Director, Worldwide Regulatory Affairs, Parexel International.
- 2.40 BRANDS-LEARNING FROM PARRALLEL MARKETS
- The principles of creating a great brand
- 360° perspective
- Drawing on future market and consumer trends
- Creating proposition that work across cultural boundaries
- Evoking the brand personality
- Peter Shaw, Director, Corporate Edge.
- 3.20 ADVERTISING COSMETICS AND HEALTHCARE PRODUCTS
- Advertising self-regulation - an overview
- Why self-regulation and not law
- The British codes of advertising and sales promotion
- Points to watch when advertising cosmetics and healthcare products
- Getting advice before you publish
- Sarah Coe, Copy Advice Executive, Committee of Advertising Practice.
- 4.00 Chairman’s Closing Remarks followed by Afternoon Tea
- Close Of Conference
AbstractMoving forward within the 21st century, more and more cosmetic companies are increasing development and marketing of products that provide therapeutic effects for users. Cosmeceuticals is a blend of Cosmetics and Pharmaceuticals which has appeared only in the nineties. There is a growing recognition that one of the key ways in which companies are going to obtain maximum return on their investment in cosmetics is to include strong capabilities in the field of cosmeceuticals.
Cosmetics and Healthcare will address the developments and advances in cosmetic and drug research, which have led to advances throughout science and industry. The conference will look at the technologies underlying cosmeceuticals, in addition to applying cosmetics to drug discovery and development strategies. The economic, regulatory and legal issues within the industry will also be discussed. The conference aims to bring together leaders in the fields of cosmeceuticals, medicine, and pharmaceutical development to offer an insight into the application of cosmetics in medicine and to analyse the future of the industry.
A unique opportunity to learn from leading industry experts including:
- Dr Freddy Van Goethen, Principal Scientist, Study Director Genetic & In Vitro Toxicology Johnson & Johnson
- Dr Stuart Freeman, Director, Toxicology, GlaxoSmithKline Consumer Healthcare
- Frank Massino, Chairman & Chief Executive Officer, Senetek
- Dr Karl Lintner, Managing Director, Sederma
- Dr Bart De Wever, Business Development Director, SkinEthic Laboratories
Also including presentations from:
Pfizer, Procter & Gamble & Committee of Advertising Practice
Key benefits of attending
INGREDIENTS: gain an insight into the use of botanicals
DELIVERY TECHNOLOGIES: discover the latest developments
TESTING: learn about cutting edge in vitro technologies
CLINICAL TRIALS: keep up to date with the latest strategies
KEY DECISION-MAKERS: meet and exchange ideas with experts in the field
“Excellent very informative conference” Dr Richard Evans, Scientist, Unilever Research
“Assuring cosmetic safety without the use of animals is a critical issue for the industry, alternative methods have to be developed and implemented as a matter of priority” Dr Stuart Freeman, Director, Toxicology, GlaxoSmithKline Consumer Healthcare
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
